Stanford M. Shoor, MD - Rheumatology

Dr. Stanford Shoor reviews medical content for Healthwise, a nonprofit organization with a mission to help people make better health decisions. Dr. Shoor, an internist specializing in rheumatology, has been on the Clinical Faculty of Stanford University since 1986 and currently holds an appointment as an Adjunct Clinical Professor of Medicine and Rheumatology.

Dr. Shoor has served as principal investigator or co-investigator for a number of research projects sponsored by Kaiser Health Plan and the Stanford Arthritis Center. He serves on the medical review boards for the Journal of General Internal Medicine, Permanente Journal, ACP Journal, and the Evidence Based Medicine section of the British Medical Journal (BMJ).

Board Certifications

American Board of Internal Medicine—1982

American Board of Internal Medicine, Subspecialty: Rheumatology—1984

Healthwise Knowledgebase Topics Reviewed

Gout

Juvenile Rheumatoid Arthritis

Medical Tests: Antinuclear Antibodies, Erythrocyte Sedimentation Rate, Rheumatoid Factor

Osteoarthritis

Raynaud's Syndrome

Rheumatoid Arthritis

Sjögren's Syndrome

Systemic Lupus Erythematosus

Education

M.D.: Stanford University School of Medicine, 1979

Internship, University of Washington, 1978–1980

Residency, University of Washington, 1980–1982

Robert Wood Johnson Clinical Scholar, Stanford University School of Medicine, 1982–1984

Fellowship in Immunology, Stanford University School of Medicine, 1982–1984

Academic Appointments

Adjunct Clinical Professor of Medicine and Rheumatology, Stanford University, 1986–present

Hospital Affiliations

Staff Director, Mid-Peninsula Health Service, 1973–1975

Internist, Rheumatology, Kaiser Foundation Hospital, Santa Clara, California, 1984–present

Chief of Professional Education, Kaiser Foundation Hospital, Santa Clara, 1988–present

Professional Affiliations

American College of Physicians

American College of Rheumatology

Selected Publications

1. O'Leary A, Shoor SM, Lorig K, Holman HR (1988). A cognitive-behavioral treatment for rheumatoid arthritis. Health Psychology 7(6): 527–544.
2. Lorig K, Chastain RL, Ung E, Shoor S, Holman HR (1989). Development and evaluation of a scale to measure perceived self-efficacy in people with arthritis. Arthritis and Rheumatology 32(1): 37–44.
3. Graham, DJ, Campen D, Hui R, Spence M, Cheetham C, Shoor S, Ray W (2005). Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective nonsteroidal anti-inflammatory drugs: Nested case control study. Lancet, 365(9468): 475–481.
4. Herrinton L, Liu L, Shoor S, Mines D (2008). Risk of lymphoproliferative cancer among patients with severe rheumatoid arthritis, 1996-2002. Annals of the Rheumatic Diseases, 67(4): 574–575.

Financial Disclosure

This reviewer reported no financial conflicts.

© 1995-2010 Healthwise, Incorporated. Healthwise, Healthwise for every health decision, and the Healthwise logo are trademarks of Healthwise, Incorporated.